Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 208 Press Releases
–
26 July 2024
26 July 2024
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
PARIS, FRANCE, 26 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today two positive opinions by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for two different rare cholestatic liver disease medicines from the…
–
25 July 2024
25 July 2024
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
PARIS, FRANCE, 25 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024.
–
11 July 2024
11 July 2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
PARIS, FRANCE, 11 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Foreseen Biotechnology (Foreseen) today announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed…
–
02 July 2024
02 July 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
PARIS, FRANCE, 2 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today confirmation of an expanded collaboration and license agreement with Exelixis, Inc. for the development of Cabometyx® (cabozantinib) in advanced pancreatic neuroendocrine tumors (pNETs) and advanced extra-pancreatic neuroendocrine…
Your dedicated contacts
-
Amy Wolf
Vice President, Corporate Brand Strategy and Communications
-
-
Ioana Piscociu
Senior Manager, Media Relations
-
Related links